Pharmaceuticals

Pharmaceuticals Categories

Pharmaceuticals Related Videos - powered by YouTube API

Wallstrip - Onyx Pharmaceuticals, Inc. (ONXX) (12-4-07) Is life worth living? That depends on the liver... and Onyx Pharmaceuticals, Inc. (ONXX).

Pharmaceuticals and Toxins All drugs come with side effects, and there are many other toxins in the world our dogs may have access to. So many pharmaceutical drugs have natural alternatives without the side effects but are just as effective. To see more topics and a menu for our clips please visit www.canine-health-concern.org.uk/VideoLibrary.html

ClindaReach® by DUSA Pharmaceuticals ClindaReach® is indicated for the treatment of acne vulgaris and is only available by prescription. Ask your dermatologist if ClindaReach® is right for you. ClindaReach® provides you with a new way of applying prescription strength medication to all hard-to-reach areas, including the back, with the unique EasyReach® applicator. Important Safety Information ClindaReach® (Clindamycin Phosphate Topical Solution USP, 1%) is indicated for acne vulgaris and is available only by prescription. Ask your doctor if ClindaReach® is right for you. Do not use ClindaReach® if you are allergic to or have hypersensitivity to Clindamycin, Lincomycin, or to any of the components in ClindaReach®, or if you have a history of regional enteritis, ulcerative colitis or a history of antibiotic-associated colitis. Tell your doctor if you are taking neuromuscular blocking agents, as Clindamycin has been shown to have neuromuscular blocking properties. Tell your doctor if you are pregnant and/or nursing. Clindamycin, the antibiotic in ClindaReach® may cause diarrhea, bloody diarrhea and pseudomembranous colitis. If you experience diarrhea, stop using ClindaReach® and call your doctor immediately. Side effects may include burning, itching, dryness, redness and peeling. Please see full prescribing information at: dusapharma.com

News Update: Arena Pharmaceuticals Says Japan's Eisai to Market its Obesity Durg Lorcaserin Jul 1, 2010 -- Arena Pharmaceuticals (ARNA) and Japan's Eisai ink a deal worth potentially more than $1.3 billion to fund commercialization of an obesity drug that could become Arena's first product. Arena said Eisai will pay $50 million upfront for rights to sell lorcaserin in the US In addition, Arena could get as much as $160 million in payments for reaching certain development targets and getting the drug approved by regulators, plus a $1.16 billion one-time payment in the future based on the level of annual sales. Arena will manufacture the drug and Eisai will distribute it in the US Arena keeps the rights in other countries. **

Merrion Pharmaceuticals, CEO John Lynch At Merrion Pharmaceuticals our team of researchers and professionals invest their skills and energy in developing new medicines that will make a difference to International health care. We are inventing distinctly different and new medicinal products, which provide a clear patient benefit, as well as meeting an unmet medical need.